

Supplemental Material

Supplemental Table 1

	Panel	Exome	Genome
Fulgent	Yes	No	No
Ambry	Yes	Yes	No
ARUP	Yes	Yes	No
Chicago	Yes	Yes	No
CHOP	Yes	Yes	No
Invitae	Yes	Yes	No
Mayo	Yes	Yes	No
Quest	Yes	Yes	No
Stanford	Yes	Yes	No
UW	Yes	Yes	No
CMH	Yes	Yes	Yes
GeneDx	Yes	Yes	Yes
SickKids	Yes	Yes	Yes
LMM	Yes	No	Yes
NYGC	Yes	No	Yes
HudsonAlpha	No	No	Yes
Illumina	No	No	Yes
Rady	No	No	Yes
Variantyx	No	No	Yes

Supplemental Table 2

Race/Ethnicity	Volume	Percentage
White/European	436267	56.6%
Hispanic	75879	9.8%
Black/African/AA	61061	7.9%
Asian	31067	4.0%
Ashkenazi Jewish	15074	2.0%
AMR/Amer. Indian	7718	1.0%
Middle Eastern	1932	0.3%
Mixed/Other	80399	10.4%
Not Provided	61144	7.9%
Total	770541	

Supplemental Table 3

Test Type	Disease Area	Average Genes per Test	Test Volume	Inconclusives with VUS (panel)	%	Positives (Panel)	%
Panel	Cardiovascular	59	33849	15184	45%	4318	13%
Panel	Dermatologic	61	262	148	56%	24	9%
Panel	Dysmorphic/Skeletal	33	4088	1137	28%	1031	25%
Panel	Endocrine	24	1793	338	19%	222	12%
Panel	Hearing Loss	136	4267	2626	62%	1081	25%
Panel	Hematologic/Rheumatologic/Immunolo	24	2869	771	27%	209	7%
Panel	Hereditary Cancer/Cancer Syndrome	43	299076	78977	26%	30847	10%
Panel	Metabolic	33	2003	538	27%	288	14%
Panel	Neurodevelopmental/ID/Autism	135	6245	2852	46%	441	7%
Panel	Neurological/Muscular/Neuromuscular	72	23989	10185	42%	2155	9%
Panel	Renal/GI	141	11616	6765	58%	2721	23%
Panel	Retinal Disease	42	218	59	27%	58	27%
Panel	Other	58	8222	2472	30%	1006	12%
Panel	Not specified	54	1065315	355565	33%	105832	10%
Test Type	Disease Area		Test Volume	Inconclusives with VUS (panel)	%	Positives (Panel)	%
Genomic	Cardiovascular		110	22	20%	28	25%
Genomic	Dysmorphic/Skeletal		217	55	25%	42	19%
Genomic	Hematologic/Rheumatologic/Immunologic		82	27	33%	12	15%
Genomic	Metabolic		64	5	8%	9	14%
Genomic	Neurodevelopmental/ID/Autism		2455	739	30%	486	20%
Genomic	Neurological/Muscular/Neuromuscular		325	98	30%	36	11%
Genomic	Other/Too low volume		1766				
Genomic	Not specified		43475				

Data Collection Instructions Provided to Laboratories

Duration: Limit analysis to 2 years: 1/1/2020 - 12/31/21

Testing context:

- Diagnostic (symptomatic) germline sequencing testing only (NGS or Sanger)
- Exclude somatic, carrier, population screening, familial variant, genotyping, or any testing that does not report VUSs

Panels:

- Include panels where analysis is limited to panel genes only
- Exclude “exome slice” type of analyses where analysis may reflex to a wider examination of genes or is customized from entire genome by ordering provider
- Assumption: All variants in a panel are classified and VUS and above reported; if your lab reports fewer variants than this, please include those methods when sharing your data (e.g., do you exclude VUS-Favor Benign?, do you restrict reporting to only variants with a good match to phenotype?, etc)
- Panel size groupings for analysis (you may optionally include the exact panel sizes for each test):
 - 1
 - 2-10
 - 11-25
 - 26-50
 - 51-100
 - 101-200
 - >200
- Disease areas (you may optionally include the exact test name for each test):
 - Cardiovascular
 - Hereditary Cancer/Cancer Syndrome
 - Neurodevelopmental/ID/Autism
 - Neurological/Muscular/Neuromuscular
 - Retinal Disease
 - Hearing Loss
 - Renal/GI
 - Endocrine
 - Metabolic
 - Dysmorphic/Skeletal
 - Hematologic/Rheumatologic/Immunologic
 - Dermatologic
 - Other

Genome and Exome:

- Include only genomic testing that makes it clear to the provider that the scope of analysis includes all genes
- Exclude panel testing performed on a exome/genome backbone for lab workflow only if reporting is restricted to the panel
- Separate data by exome vs genome
- Separate cases by trio status:
 - "at least trio" (e.g., proband plus both parents, quads with both parents, etc)
 - "less than trio" (e.g., proband only or proband plus other familial members without both parents)

Primary data collection variables:

- Number of Inconclusive cases with at least one VUS
 - Exclude "Positive" cases where a diagnosis was identified but additional VUSs were also reported from this category, but we have a separate category (positives with VUS) to report on this
 - Include cases/VUSs regardless of whether they are VUSs in GUSs vs VUSs in known genes
 - Ideally include only inconclusives due to, at least in part, VUS, not those that are solely inconclusive due to other reasons without any VUS (e.g., unclear gene-phenotype match, single het recessive cases). If it is not possible to separate, then note this in your caveats
 - Do not consider secondary findings when assessing the result (e.g., if the diagnostic test result is inconclusive due to a VUS, but you also have a pathogenic secondary finding reported, treat the cases as inconclusive due to the VUS) - there is a separate field where groups can optionally report the number of cases with a secondary/incidental finding (you could add a note on the site-specific details tab to indicate the range of secondary/incidental findings reported by your lab) - you do not need to delineate what the SF/IF cases had in terms of their dx result
- Results should be based on initial reports/classifications (ignore reclassifications); if not possible, explain in caveats
- Optional data collection for non-case centric data:
 - Total VUSs reported in panels vs exome and/or genome
 - We prefer that this be total VUS 'observations' such that if a given VUS was observed in 10 cases, you would count that 10 times. If you cannot count VUS observations, and can only count unique VUSs' then please describe that in site-specific details
- Optional data collection for VUS subcategory
 - Written as VUS-FP, VUS-Equivocal, VUS-FB but these can map to whatever terms you use in your lab; you can use only those categories you use (VUS-Suspicious/Favor Path only for example)

Optional data cleaning:

- You may exclude cases where a VUS was included in the genome/exome report only because it was previously reported by a panel test

Race/ethnicity/ancestry:

- If available, please include the general breakdown of race/ethnicity/ancestry, as you collect it, for your laboratory in the site-specific tab
- You may optionally segregate your data by race/ethnicity/ancestry (simply add more lines in the spreadsheet and separate data by race/ethnicity/ancestry (add column for race/ethnicity/ancestry field)

Site-specific data to collect:

- Lab Name
- Primary contact for project
- Lab website URL
- Race/ethnicity/ancestry breakdown of your test population if collected
- Please describe any reporting methods or practices that are relevant to this project and your site:
- Please include any VUS reporting policies/practices for your lab. An example shown below:
 - If a case is positive with a Path variant that supports dx we don't report VUS
 - We don't report syn VUS if the variant is not predicted to affect splicing.
 - We only report +/- 10bp into the intron
- Describe any caveats of your data collection:
- Please list individuals who contributed substantially to the oversight, data collection, analysis or manuscript writing for this project
 - Note, this can be updated later if things change